Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, recently announced an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of $9.00 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase an aggregate of 3,333,333 shares of common stock at a public offering price of $8.999 per pre-funded warrant. Aggregate gross proceeds from the offering totaled approximately $100 million, before deducting underwriting discounts and commissions and other offering expenses payable by Voyager Therapeutics. In addition, Voyager has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,666,665 shares of its common stock at the public offering price, less underwriting discounts and commissions.

The WilmerHale team advising Voyager Therapeutics was led by Brian Johnson and Avery Reaves and included Sarah Matchett and Frank Wang.